Merck to introduce three new Phase 3 Keytruda studies

After revealing positive data from a phase 1b/2 Keynote-365 trial, Merck has stated it will run phase 3 studies testing Keytruda in tandem with Lynparza, the PARP inhibitor it shares with AstraZeneca; in a cocktail containing the chemotherapy docetaxel and steroid prednisone; and alongside Xtandi, a hot prostate cancer drug from Pfizer and Astellas.

Click here to view the entire article